NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Pownall
Mark
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics*; D000069287:Capecitabine; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics; D056736:Drug Recalls; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics; D006801:Humans; D000077341:Lapatinib; D009362:Neoplasm Metastasis; D019057:Quality-Adjusted Life Years; D011799:Quinazolines / Q000008:administration & dosage / Q000191:economics / Q000600:supply & distribution; D016896:Treatment Outcome; D006113:United Kingdom
D011799:Quinazolines; D000077341:Lapatinib; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil